Albumin ( DrugBank: - )

3 diseases

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02479802 (ClinicalTrials.gov)	November 2014	10/6/2015	Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis	Pilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Biological: Albumin	Instituto Grifols, S.A.	NULL	Completed	18 Years	70 Years	All	13	Phase 2	Spain
2	EUCTR2013-004842-40-ES (EUCTR)	09/05/2014	07/03/2014	Pilot study to evaluate the effect of plasma exchange with albumin in patients with amyotrophic lateral sclerosis	Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis - Albumin in ALS	Amytrophic Lateral Sclerosis (ALS) MedDRA version: 16.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Albutein 5% INN or Proposed INN: albúmina humana Other descriptive name: HUMAN ALBUMIN SOLUTION	Instituto Grifols S.A.	NULL	Not Recruiting			Female: yes Male: yes		Phase 4	Spain

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04303416 (ClinicalTrials.gov)	March 9, 2020	6/3/2020	Plasma Exchange With Albumin in AMN Patients	Effect of Plasma Exchange With Albumin in Patients With Adrenomyeloneuropathy: Unicentric, Single Arm, Proof of Concept Study.	Adrenomyeloneuropathy;Adrenoleukodystrophy	Drug: Albumin solution	Onofre, Aurora Pujol, M.D.	NULL	Completed	18 Years	65 Years	Male	5	Phase 2/Phase 3	Spain
2	EUCTR2019-004733-17-ES (EUCTR)	25/02/2020	20/12/2019	Plasma exchange by albumin replacement in Adrenomyeloneuropathy	Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial	Adrenomyeloneuropathy MedDRA version: 20.0;Level: LLT;Classification code 10069075;Term: Adrenomyeloneuropathy without cerebral involvement;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Albunorm® 5%, Product Name: Albumin INN or Proposed INN: ALBUMIN Other descriptive name: ALBUMIN	Aurora Pujol Onofre	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	5	Phase 2	Spain

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00769028 (ClinicalTrials.gov)	December 2008	7/10/2008	AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis	A Double-Blind Placebo-Controlled Pilot Study of Safety and Tolerability of AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis	Systemic Sclerosis	Drug: Hyperimmune caprine serum;Drug: Albumin	Daval International Limited	NULL	Active, not recruiting	18 Years	N/A	Both	20	Phase 2	United Kingdom